The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cronos Australia (CAU) has received its first shipment of Peace Naturals branded cannabis oils
  • Peace Naturals will be sold by Sigma, through its retail pharmacies
  • Cronos is up 13.16 per cent on the market this morning, trading at 22¢ per share

Cronos Australia (CAU) has received its first shipment of Peace Naturals branded cannabis oils.

The products were supplied by Peace Naturals Project, a subsidiary of the company’s major shareholder Cronos Group.

Peace Naturals was the first group to be licensed to sell medicinal cannabis oils. Currently, the oils are sold to patients in Canada and Germany.

Cronos Australia was formed to take advantage of opportunities relating to the emerging cannabis industry both domestically and internationally.

Last year, the company signed a distribution agreement with Sigma to sell its products in Australia.

Under the agreement, Peace Naturals will be prescribed to patients under the SAS-B Scheme, or by an Authorised Prescriber, which are expected to be distributed by Sigma through its significant nationwide network of retail pharmacies.

CEO Rodney Cocks is pleased with the first shipment.

“The receipt of the first shipment of Peace Naturals medicinal cannabis oils by Cronos Australia is an important step to making quality cannabinoid products available to Australian patients,” he said.

“This marks an important milestone in the company’s Australian medicinal cannabis operations,” he added.

Recently, the company formed a joint venture with A&S Branding. The two companies will develop products using cannabidiol skincare and other products.

Cronos is up 13.16 per cent on the market this morning, trading at 22¢ per share at 10:31 am AEDT.

CAU by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…